FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome

The FDA placed a full clinical hold on Aardvark Therapeutics' drug for extreme hunger tied to Prader-Willi syndrome, halting all late-stage trials. The decision materially delays the program and raises regulatory risk for the company’s lead asset. This is a negative development for Aardvark and could pressure shares.

Analysis

The FDA placed a full clinical hold on Aardvark Therapeutics' drug for extreme hunger tied to Prader-Willi syndrome, halting all late-stage trials. The decision materially delays the program and raises regulatory risk for the company’s lead asset. This is a negative development for Aardvark and could pressure shares.